Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro.
MUC1 protein is an attractive target for anticancer drug delivery owing to its overexpression in most adenocarcinomas. In this study, a reported MUC1 protein aptamer is exploited as the targeting agent of a nanoparticle-based drug delivery system. Paclitaxel (PTX) loaded poly (lactic-co-glycolic-aci...
Main Authors: | Chenchen Yu, Yan Hu, Jinhong Duan, Wei Yuan, Chen Wang, Haiyan Xu, Xian-Da Yang |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3164674?pdf=render |
Similar Items
-
Chapter 7 Aptamer-Nanoparticle Bioconjugates for Drug Delivery
by: Schäfer, Thomas
Published: (2012) -
Chapter 7 Aptamer-Nanoparticle Bioconjugates for Drug Delivery
Published: (2012) -
Novel MUC1 aptamer selectively delivers cytotoxic agent to cancer cells in vitro.
by: Yan Hu, et al.
Published: (2012-01-01) -
Novel Bispecific Aptamer Enhances Immune Cytotoxicity Against MUC1-Positive Tumor Cells by MUC1-CD16 Dual Targeting
by: Zhaoyi Li, et al.
Published: (2019-01-01) -
A Novel Approach of Targeted Immunotherapy against Adenocarcinoma Cells with Nanoparticles Modified by CD16 and MUC1 Aptamers
by: Lianyuan Yu, et al.
Published: (2015-01-01)